*For medical professionals for reference
Hurry up
sorting: hannahAudit expert: Professor Tianzhuang
Recently, recent,At the 2024 Chinese Physician Society Annual Meeting (CSC 2024), Professor Tianzhuang from Beijing Union Hospital from the "Guidelines for the Diagnosis and Treatment 2024" (Guidelines for China False False Failure Diagnosis and Treatment 2024 "The key points of the following referred to as "Guide") have been interpreted in depth.
The update of this guide is not only based on the latest scientific research results, but also fully considers the new challenges in clinical practice, providing the standardized diagnosis and treatment of More detailed guidance.The following are the core points of this update.
Figure 1. Professor Tianzhuang Lecture
,
Introduce more Chinese evidence
Among people aged 65-79 and over 80 years old, the prevalence of standardized heart failure was 0.57%, 3.86%, and 7.55%, respectively.Through standardized treatment, the mortality of heart failure decreased from 15.45%in the 1980s to 6.2%in 2000. The main cause of death was left heart failure (59%) at a time, arrhythmia (13%) and sudden heart death (13%of 13%), But more data still needs to be collected to understand the real situation of the current mortality.
Professor Tianzhuang said that the new guide also affirmed the application of "Hydin Bouncing in the Hero-Pukeno system to the patient failure of the heart failure" proposed by our scholars.At the same time, the efficacy of traditional Chinese medicine in the treatment of heart failure has gradually been recognized.
2. The classification and diagnostic criteria for updating heart failure
Category of heart failure has always been a complexquestion.Traditionally, the classification method of ejection score (EF value) has been deeply rooted in the hearts of the people, but in recent years, with the in -depth research of the heart failure mechanism, the new classification method has gradually emerged.Especially for patients with improved EF values after treatment, the new guide particularly emphasizes the importance of continuing treatment and sets up a new subtype to better guide clinical practice (Figure 2).
Figure 2
3.>
Prevention and early intervention of heart failure are the key to reducing its incidence and disease mortality.Common risk factors for heart failure such as hypertension, coronary heart disease, and diabetes should be actively controlled to improve the patients awareness and standard rate.The new guide divides heart failure into 4 stages (Figure 3), and newly increases stage A (risk of heart failure) and stage B (early heart failure), remind doctors to pay attention to high -risk people during the treatment process, control risk factors, especially especiallyIt is necessary to pay attention to the damage of the heart structure and function of the tumor treatment, closely monitor, and adjust the medication in time to reduce the possibility of heart failure.
Figure 3
In addition, some hypoglycemic drugs to reduce heart failure riskIt is increasingly valued and provides new means for the prevention of heart failure.Professor Tianzhuang said that patients with diabetic patients with high-risk factors of cardiovascular diseases or cardiovascular diseases are recommended in the new guide.Detecting the level of Elison Peptide (BNP or NTPROBNP) to screen for high -risk groups (heart failure A).
4. Improvement of drug treatment and New Four Condition therapy
Drug treatment of heart failure has been obtained in recent yearsSignificant progress.The traditional "Golden Triangle" drug [/vascular tension II II receptor antagonist (ACEI/ARB), β-blocker, aldehyde solid antagonist antagonist] is still the cornerstone, butThe continuous emergence of new drugs has enriched the treatment plan.Especially the proposal of Four Conditional therapy (ARNI/ACEI/ARB, β-blocker, aldosterone receptor antagonist, SGLT-2i), provided new new in patients with heart failure, provided a newPowerful weapons.
At the same time, new drugs such as soluble birdyototenase excitement also provide useful supplements for heart failure treatment.For example, Villixi can repair the signaling pathway of damaged cells, and it can also further improve the prognosis of patients with heart failure under the background of the drug treatment recommended by the guide.Therefore, the new guideline recommends the recent incident of heart failure, NYHAII ~ IV, and the left ventricular ejaculation score (LVEF)
